Comparing ImmuCell (ICCC) and Its Rivals

ImmuCell (NASDAQ:ICCC) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare ImmuCell to similar businesses based on the strength of its institutional ownership, analyst recommendations, profitability, risk, dividends, valuation and earnings.

Earnings and Valuation

This table compares ImmuCell and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ImmuCell	$30.68 million	-$1.04 million	127.75
ImmuCell Competitors	$3.54 billion	$3.17 billion	553.75

ImmuCell’s competitors have higher revenue and earnings than ImmuCell. ImmuCell is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current recommendations for ImmuCell and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	0	1	0	0	2.00
ImmuCell Competitors	7820	13783	25793	1036	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 24.81%. Given ImmuCell’s competitors stronger consensus rating and higher possible upside, analysts plainly believe ImmuCell has less favorable growth aspects than its competitors.

Volatility and Risk

ImmuCell has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, ImmuCell’s competitors have a beta of -0.05, indicating that their average share price is 105% less volatile than the S&P 500.

Insider & Institutional Ownership

13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 5.7% of ImmuCell shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares ImmuCell and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ImmuCell	2.57%	2.69%	1.76%
ImmuCell Competitors	-2,393.19%	-220.45%	-16.12%

Summary

ImmuCell competitors beat ImmuCell on 9 of the 13 factors compared.

About ImmuCell

ImmuCell Corporation is a biotechnology and animal health company headquartered in Portland, Maine. The company develops, manufactures, and commercializes products designed to support the health and productivity of livestock, with a primary focus on cattle. ImmuCell’s products include FirstStep Calf Health, an on-farm diagnostic test that helps dairy and beef producers assess whether newborn calves have received adequate passive immunity from colostrum. The company also develops antibody-based products intended to help prevent or manage common diseases affecting young livestock, including neonatal calf diarrhea.